Overcoming immunotherapy resistance in melanoma defective of IFN-g signaling
Melanoma loss of IFN-g signaling is a major mechanism of resistance to immune checkpoint blockers such as anti-CTLA-4 and anti-PD-1, a prominent type of immunotherapies offering unprecedented therapeutic hopes to melanoma patients. However, strategies of overcoming this resistance have been elusive.
Recent Comments
Dear Colleagues,
I'd like to share our recent publication on Gfi1 as a key regulator of T cell exhaustion. Please help take a read. Thanks.
Lewis
I woud lik to share our most recently published story with the research community, wherein we report an indispensable role of HIF1a in driving IFN-g induction in hypoxic T cells and anti-tumor immunity elicited by immune checkpoint blockade therapies.